Minimally Invasive Glaucoma Surgery (MIGS) Devices Market to Grow $912 Million by 2023

"Increased global glaucoma incidence, recurrent glaucoma with other eye diseases, and an increase in preference for the ab interno approach to treatment of glaucoma facilitate market growth. The elderly population develops glaucoma such as mild to moderate glaucoma, primary and secondary corneal occlusive glaucoma, and promotes growth in this market. Ineffective drug delivery in glaucoma treatment promoted market growth by facilitating the transition from drug therapy to minimally invasive glaucoma surgery (MIGS) devices."

New report published "Minimally Invasive Glaucoma Surgery (MIGS) Devices Market by Surgery, Target, Product, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023", by Allied Market Research. The global minimally invasive glaucoma surgery (MIGS) devices market was valued at $144 million in 2016, and is projected to reach $912 million by 2023, growing at a CAGR of 30.1% from 2017 to 2023. The glaucoma in conjunction with cataract surgery segment accounted for three-fifths share of the market in 2016.

Get Access to TOC / Sample Report @ https://www.alliedmarketresearch.com/request-sample/4547?utm_source=opr_

Increase in focus on developing combination surgeries for treatment of glaucoma, high prevalence of open-angle glaucoma, and rapid rise in geriatric population are anticipated to drive the growth of the minimally invasive glaucoma surgery (MIGS) devices market. In addition, increase in the changing demographics leading to obesity, diabetes, and varied eye disorders supplement the market growth. However, dearth of skilled professionals to perform minimally invasive glaucoma surgeries efficiently and high cost of the MIGS device hamper the market growth. Conversely, surge in investment by manufacturers in the emerging economies and rise in initiatives to reduce the burden of glaucoma globally are anticipated to offer lucrative opportunities for market expansion.

The trabecular meshwork target dominated the global MIGS devices market accounting for half of the total market share in 2016, and is set to maintain the dominance throughout the forecast period. At present, there are a few MIGS devices used to treat glaucoma by targeting the TM, namely, Trabectome, iStent, Hydrus, gonioscopy-assisted transluminal trabeculotomy (GATT), and excimer laser trabeculotomy (ELT). Extensive use of aforementioned products in the treatment of glaucoma contributed to the dominance of trabecular meshwork segment in the global MIGS devices market. Whereas, suprachoroidal space target is anticipated to grow at the fastest pace, registering a CAGR of 33.7% from 2017-2023.

Key Findings of the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market:

• The MIGS stents generated the highest revenue in 2016, and is anticipated to do so throughout the forecast period, registering a CAGR of 27.1% from 2017 to 2023.
• Eye hospitals dominated the market, accounting for maximum share in 2016 and is expected to witness a CAGR of 26.3% from 2017 to 2023.
• North America dominated the global minimally invasive glaucoma surgery (MIGS) market, accounting for maximum share in 2016 and is expected to retain the same trend during 2017 to 2023.
• The MIGS shunts product segment is expected to witness the highest growth rate during the forecast period.
• Japan accounted for one-fourth share of the Asia-Pacific minimally invasive glaucoma surgery (MIGS) devices market in 2016.

Asia-Pacific witnessed highest growth rate for the minimally invasive glaucoma surgery (MIGS) devices market throughout the forecast period, owing to high population density and increase in geriatric population. In addition, rise in incidence of conditions such as moderate glaucoma and open-angle glaucoma in India and China boosts the market growth.

Send Enquiry on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/4547?utm_source=opr_

The key players operating in the minimally invasive glaucoma surgery (MIGS) devices market adopted product launch as one of their key developmental strategies. The major companies profiled in the report include Alcon Inc. (Novartis), Ellex Medical Lasers Ltd., Glaukos Corporation, Allergan Plc, Santen Pharmaceutical Co., Ltd., Lumenis, Ivantis, Inc., SOLX, Inc, iSTAR Medical, and InnFocus Inc. Other players (profiles not included in the report) in the value chain analysis include, Bausch & Lomb Inc., Neomedix Corporation, IOPtima, Abbott Medical Optics, Inc., Topcon Corporation, New World Medical, Inc, Carl-Zeiss AG, and Optonol Ltd..

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.